Published in Sarcoma on July 18, 2012
Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol (2017) 0.75
Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO). Invest New Drugs (2015) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer (2007) 2.62
Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol (2009) 2.26
Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol (2004) 1.82
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2011) 1.79
Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol (2001) 1.52
Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer (2009) 1.36
Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther (2009) 1.33
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol (2006) 1.30
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant (2007) 1.23
How to treat the Ewing's family of sarcomas in adult patients. Oncologist (2006) 1.23
Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer (2010) 1.20
Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin Oncol (1996) 1.20
Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer (2006) 1.09
Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma (2011) 1.07
Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. J Clin Pharmacol (2008) 0.94
Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science (2000) 13.62
Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell (2001) 8.60
An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell (2001) 4.81
CDKN2A mutations in multiple primary melanomas. N Engl J Med (1998) 3.52
Review of criteria used to measure library effectiveness. Bull Med Libr Assoc (1972) 3.46
Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am (1999) 3.45
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Identification of novel stress-induced genes downstream of chop. EMBO J (1998) 2.93
Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol (2001) 2.70
Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys (1991) 2.48
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol (1998) 2.42
Characterization of the human beta-crystallin gene Hu beta A3/A1 reveals ancestral relationships among the beta gamma-crystallin superfamily. J Biol Chem (1986) 2.31
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am (1996) 2.26
Viral genome organizer: a system for analyzing complete viral genomes. Virus Res (2000) 2.24
A two-step fibrinogen--fibrin transition in blood coagulation. Nature (1978) 2.15
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. EMBO J (2000) 2.05
Receptor-independent activators of heterotrimeric G-protein signaling pathways. J Biol Chem (1999) 2.00
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis (2010) 1.98
Allograft reconstruction of the acetabulum after resection of stage-IIB sarcoma. Intermediate-term results. J Bone Joint Surg Am (1997) 1.93
Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol (1990) 1.88
The surgical margin in soft-tissue sarcoma. J Bone Joint Surg Am (1989) 1.86
Safety and efficacy of low anterior resection for rectal cancer: 681 consecutive cases from a specialty service. Ann Surg (1999) 1.84
Effect of gastrin II on the motility of the gastrointestinal tract. Lancet (1966) 1.83
Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys (1994) 1.82
An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys (2000) 1.82
The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation (1996) 1.75
Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet (1999) 1.74
Molecular biology of colorectal cancer. Curr Probl Cancer (1998) 1.70
Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys (1995) 1.70
Clinical trials in cancer: the role of surrogate patients in defining what constitutes an ethically acceptable clinical experiment. Br J Cancer (1989) 1.68
How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol (1988) 1.65
Linkage of a microsatellite marker to the canine copper toxicosis locus in Bedlington terriers. Am J Vet Res (1997) 1.65
Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins. J Biol Chem (2001) 1.64
The influence of anatomic location on functional outcome in lower-extremity soft-tissue sarcoma. Ann Surg Oncol (2004) 1.64
Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer (2004) 1.64
The impact of residual disease on local recurrence in patients treated by initial unplanned resection for soft tissue sarcoma of the extremity. J Surg Oncol (1997) 1.61
Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer (1994) 1.60
Paratesticular sarcoma: failure patterns after definitive local therapy. J Urol (1999) 1.59
Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem (1992) 1.59
Adult paratesticular sarcomas: a review of 21 cases. J Urol (1991) 1.59
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer (1986) 1.53
Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol (1996) 1.50
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys (1993) 1.50
The inguinal sarcoma: a review of five cases. Can J Surg (1990) 1.48
Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys (1995) 1.44
Prospective evaluation of early versus delayed laparoscopic cholecystectomy for treatment of acute cholecystitis. Am Surg (2000) 1.44
Management of stage II seminoma. J Clin Oncol (1998) 1.43
Mixed hydroxypyridinonate ligands as iron chelators. Inorg Chem (2000) 1.43
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study. Int J Radiat Oncol Biol Phys (1991) 1.43
Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br (2001) 1.43
Current status of radiosurgery for arteriovenous malformations. Can J Neurol Sci (1991) 1.41
A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer (1997) 1.41
Primary non-Hodgkin's lymphoma of bone. A clinicopathologic study. Cancer (1994) 1.40
Squamous cell carcinoma of the oesophagus treated with radiation and 5-fluorouracil, with and without mitomycin C. Clin Oncol (R Coll Radiol) (2001) 1.40
Soft tissue sarcomas involving the pelvis. J Surg Oncol (2001) 1.40
Observation of an antimatter hypernucleus. Science (2010) 1.38
Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys (1995) 1.38
Prostate cancer: 7. Radiation therapy for localized disease. CMAJ (1998) 1.38
Functional outcome in amputation versus limb sparing of patients with lower extremity sarcoma: a matched case-control study. Arch Phys Med Rehabil (1999) 1.36
GLEE, a new computer program for glass electrode calibration. Talanta (2000) 1.33
Quantitative analysis of diurnal variation in volume and water content of lumbar intervertebral discs. Clin Anat (1998) 1.30
Wound-healing complications after soft-tissue sarcoma surgery. Plast Reconstr Surg (1994) 1.29
Mammographic signs as risk factors for breast cancer. Br J Cancer (1982) 1.28
Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol (2001) 1.28
Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J Exp Med (1991) 1.28
Extragonadal germ cell tumors. A 14-year Toronto experience. Cancer (1994) 1.27
Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys (1993) 1.26
Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease. J Bone Joint Surg Am (2000) 1.26
Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum (2000) 1.22
Efficacy of seven retrograde tracers, compared in multiple-labelling studies of feline motoneurones. J Neurosci Methods (1994) 1.21
Synthesis of a ligand based upon a new entry into the 3-hydroxy-N-alkyl-2(1H)-pyridinone ring system and thermodynamic evaluation of its gadolinium complex. Inorg Chem (2000) 1.21
Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood (2000) 1.21
Predictors of functional outcomes following limb salvage surgery for lower-extremity soft tissue sarcoma. J Surg Oncol (2000) 1.21
Heterogeneity of polyoma virus DNA: isolation and characterization of non-infectious small supercoiled molecules. J Mol Biol (1969) 1.18
Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol (2007) 1.18
Carcinoma of the lung: results of treatment over ten years. Ann Thorac Surg (1976) 1.17
Mutations of the p53 gene do not occur in testis cancer. Cancer Res (1993) 1.17
The local management of soft tissue sarcoma. Semin Radiat Oncol (1999) 1.17
Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery (1998) 1.13
Periprosthetic bone remodelling around a prosthesis for distal femoral tumours. Measurement by dual-energy X-ray absorptiometry (DEXA). J Bone Joint Surg Br (2000) 1.13
Non-small cell lung cancer: how oncologists want to be treated. Int J Radiat Oncol Biol Phys (1987) 1.12
Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. Biochem J (1994) 1.12
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) (2007) 1.11
Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys (1998) 1.11